Day: October 29, 2022

This year, the annual Quality in Care (QiC) Diabetes awards were held at Sanofi’s head office in Reading on 13 October. Back for the twelfth year, the in-person awards were a celebration of the best and brightest in healthcare. Recognising outstanding and innovative contributions in the field of diabetes, entries were submitted from across the UK demonstrating creativity and compassion in medical excellence and care. The awards honour initiatives that seek to improve the quality of life for people with diabetes, and the entries were judged by NHS staff, patients and industry leaders. The awards, created by the QiC Diabetes

Therapy showed faster clinical recovery for combined treatment groups Apogenix’s asunercept treatment has shown statistically significant benefits for hospitalised COVID-19 patients in its Asunctis trial. The open-label multi-centre phase 2 trial investigated the efficacy and safety of the therapy among 435 patients with moderate-to-severe COVID-19 disease. Patients were randomised equally, receiving 25, 100 or 400mg of asunercept and standard of care (SOC). Efficacy was assessed against the WHO-suggested endpoints, including time to clinical improvement according to WHO scale and mortality. The results showed strong trends for clinical efficacy in all treatment groups, indicating robust activity. Consistently, patients showed faster clinical

TB deaths increase for second year in a row and cases rise for the first time in 20 years. New data released by the World Health Organization in the Global Tuberculosis Report 2022 showed an increase in TB incidence in 2021 for the first time in almost two decades and a further increase in mortality. This included 4,400 people dying per day, prompting the Stop TB Partnership to express alarm over an increasingly dire situation and the impact it will have on people, health care systems and economies. The Stop TB Partnership urges the international community to understand the health threat posed